Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
King International Investment's 3-Year RORE % for the quarter that ended in Mar. 2026 was 60.00%.
HKSE:00928's 3-Year RORE % is ranked better than 90.91% of 198
companies
in the Medical Diagnostics & Research industry
Industry Median: -9.09
vs HKSE:00928: 60.00
King International Investment (HKSE:00928) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
King International Investment 3-Year RORE % Related Terms
King International Investment 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00928 vs TMO, DHR, NTRA: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, King International Investment's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
King International Investment 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where King International Investment's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
King International Investment (HKSE:00928) has a 3-Year RORE % of 60.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on King International Investment and its competitors. According to the industry distribution chart, King International Investment ranks #18 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 9.1%.
Is King International Investment's 3-Year RORE % too high?
King International Investment's current 3-Year RORE % is 60.00. Based on the distribution chart, King International Investment ranks #18 out of 198 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, King International Investment has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does King International Investment's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, King International Investment ranks #18 out of 198 companies for 3-Year RORE %. This places King International Investment in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on King International Investment and its competitors. King International Investment's current 3-Year RORE % is 60.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is King International Investment stock overvalued right now?
Based on GuruFocus' analysis, King International Investment (HKSE:00928) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.12 — trading 197.5% above its estimated fair value. The current 3-Year RORE % is 60.00. King International Investment's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For King International Investment (HKSE:00928), the current 3-Year RORE % is 60.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is King International Investment (HKSE:00928) Overvalued in 2026?
Based on GuruFocus' analysis, King International Investment stock appears to be overvalued.
The current stock price of HK$0.12 is trading 197.5% above its estimated GF Value™ of HK$0.04.
GuruFocus considers King International Investment to be Significantly Overvalued.
Key valuation signals for HKSE:00928:
3-Year RORE %: 60.00
GF Value™: HK$0.04 vs. price of HK$0.12 (197.5% above fair value)
No single metric tells the full story. See the HKSE:00928 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
King International Investment Ltd is an investment holding company. Its operating segments include healthcare products and services, money lending, and liquor sales, with the majority of revenue generated from the liquor sales segment. The group provides genetic testing and develops domestic healthcare equipment services. Leveraging its strengths, the group integrates health data analysis software with healthcare equipment to offer new healthcare services and products. Geographically, it derives the majority of its revenue from the PRC.
36GF Score
Get the complete analysis for HKSE:00928
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00928 has been successfully added to your 
